Challenge

Alber & Geiger assisted West Pharmaceutical, a US corporation and world market leader in medical devices, paving the way for PFAS ban exemptions for their products. The intention was to prevent disruptions in the supply of certain medical devices, where the medicinal products are inseparably connected with the devices, like it is the case with the diabetes pen or with vaccines prefilled in containers and syringes.

Strategy

Our team engaged in a multifaceted approach to safeguard the interests of the medicinal and medical devices. We provided strategic input during the consultation period with the European Chemicals Agency (ECHA), highlighting the unique needs and safety considerations of specific medical devices. This was followed by an extensive outreach to stakeholders within the European Parliament, the European Commission, and the EU member states. Our efforts focused on educating decision-makers about the indispensable role of PFAS in medicinal products and medical devices and the potential supply chain risks posed by a PFAS ban.

Results

Our advocacy efforts led to a pivotal development in the regulatory landscape on medical devices. Our targeted approach opened the door to potential derogations of several years for specific medical applications where there is substantial evidence that viable alternatives to PFAS do not exist. This ensures that essential medical devices remain available and effective, safeguarding patient care and industry stability.

Challenge

The European Central Bank’s (ECB) single supervisory mechanism decided to carry out its first audit of Greece’s four systemic banks since it was set up. Greece’s leading bank turned to Alber & Geiger for help amid shareholder complaints over irregularities during the last round of capital raising. Assistance was required to ensure a standard and short regulatory scrutiny that would have not weakened further the image and investor confidence in the bank and its management.

Strategy

Alber & Geiger approached directly the European banking regulators and pressed the European Commission and its respective Directorates to announce their clearance of alleged irregularities. We emphasized the importance of investigations being short to not harm the image of the bank and its management.

We then sought to restructure the confidence on the Greek and European financial sector vis-à-vis the EU and German lawmakers and administrators. Our message put on the spotlight the bureaucratic approach and lengthy investigation on the bank itself, highlighting the lurking threat of economic and social instability of requiring more EU taxpayers’ money to the rescue.

Results

Six months into the mandate, the media campaign against our client and repeated calls against its management came to a halt. We helped facilitate the exchange of views between our client and the European banking regulators at the highest political level. By doing so, we helped prevent another wave of economic instability in Greece’s largest systemic bank.

Challenge

The EU imposed onerous penalties on our client, the Republic of Bulgaria. €825 million of pre-accession funds were frozen. It was a response to its alleged failure to combat corruption, organized crime and misuse of EU funds. Funds worth up to €7 billion over the next six years were also at risk. The Bulgarian government turned to Alber & Geiger for help.

Strategy

Alber & Geiger’s multi-faceted approach involved sophisticated legal analysis calibrated through a dynamic, institution sensitive communications strategy. It incorporated practical considerations like staff changes in the Bulgarian government as well as larger semantic and structural reasons for misunderstandings.

Results

Alber & Geiger was able to restore trust and confidence between the European Commission and the Bulgarian government. The result was the unfreezing of the €500 million in EU funds and the de-jeopardizing of the rest of the €7 billion.